This content is protected against AI scraping.
A recent study published by the American Medical Association (AMA) shows that a single high dose of psilocybin, when paired with cognitive behavioral therapy (CBT), is significantly more effective for smoking cessation than traditional nicotine patches. In a clinical trial conducted by Johns Hopkins and the University of Alabama, participants receiving the psychedelic treatment showed a 40.5% long-term abstinence rate after six months, compared to only 10% for those using nicotine patches.
Researchers noted that unlike standard treatments, psilocybin does not interact directly with nicotine receptors. Instead, it appears to work through “higher-order psychological systems,” potentially increasing psychological flexibility and altering a person’s self-concept. This unique mechanism suggests that psychedelic therapy could have “transdiagnostic” benefits, offering a versatile tool for treating various forms of substance use disorder beyond just tobacco.
Despite these breakthrough results, outdated federal laws remain a massive roadblock to life-saving research. Even with 10 million Americans already using psychedelics and clear evidence of their safety, these restrictive regulations continue to stall the FDA approval process for a proven addiction treatment. Read the original article.
Referenced article written by . Published on March 10, 2026 by Marijuana Moment.
